Meeting
2013 Gastrointestinal Cancers Symposium
A phase II study on third-line chemotherapy combined bevacizumab with S-1 for metastatic colorectal cancer with mutated KRAS: SAVIOR study.
Authors
Akinori Takagane
Hakodate Goryokaku Hospital
Akinori Takagane , Yasuhiro Miyake , Kouji Kobayashi , Naoki Nagata , Atsushi Sato , Yutaka Ogata , Mutsumi Fukunaga , Koki Otsuka , Takao Takahashi , Hidetomo Matsumoto , Yuji Negoro , Yoshihiro Matsubara , Motoki Yoshida
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00974389
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr552)
DOI
10.1200/jco.2013.31.4_suppl.552
Abstract #
552
Poster Bd #
D52
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2016 Gastrointestinal Cancers Symposium
Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).
First Author: Matthew E. Burge
Poster
2014 ASCO Annual Meeting
UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC).
First Author: Hélène Senellart